News · 26 weeks56-57%
2025-12-142026-06-07
Mix2690d
- SEC Filings16(62%)
- Other7(27%)
- Analyst3(12%)
Latest news
25 items- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- ANALYSTTruist initiated coverage on Genmab with a new price targetTruist initiated coverage of Genmab with a rating of Buy and set a new price target of $40.00
- PRGenmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 CongressTwenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral presentations Three abstracts will show the ongoing clinical trial evaluations of the safety and efficacy of Genmab's investigational late-stage medicines, rinatabart sesutecan and petosemtamab Data evaluating epcoritamab will demonstrate outcomes across monotherapy, combination regimens and fixed-duration use, including outpatient administration and use in earlier lines of treatment Genmab A/S (NASDAQ:GMAB) announced today that 23 abstracts, including 20 abstracts evaluating epcoritamab, a su
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Genmab A/SSCHEDULE 13G/A - GENMAB A/S (0001434265) (Subject)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRMajor Shareholder AnnouncementCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; May 8, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that through shares, as of May 8, 2026, Orbis Investment Management Limited controlled the voting rights to 3,166,357 shares in Genmab A/S, which amounts to 5.08% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with c
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- ANALYSTGenmab upgraded by GoldmanGoldman upgraded Genmab from Neutral to Buy
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRMajor Shareholder AnnouncementCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of April 13, 2026, Orbis Investment Management Limited through shares controlled the voting rights to 3,114,318 shares in Genmab A/S, which amounts to 4.85% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRGenmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026Company Announcement Net sales of DARZALEX® in the first quarter of 2026 totaled USD 3,964 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,964 million in the first quarter of 2026. Net trade sales were USD 2,208 million in the U.S. and USD 1,756 million in the rest of the world. Genmab receives royalties on the wo
- PRGenmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian CancerPhase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian cancer The ongoing Phase 3 RAINFOL-04 trial will further evaluate the combination in patients with recurrent platinum-sensitive ovarian cancer (PSOC) Genmab A/S (NASDAQ:GMAB) announced today new data demonstrating that rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), evaluated in combination with bevacizumab in patients with advanced ovarian cancer, showed a safety profile consistent with the known safety pr
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRMajor Shareholder AnnouncementCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; March 30, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of March 27, 2026, Orbis Investment Management Limited through shares controlled the voting rights to 3,205,763 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people
- ANALYSTWolfe Research initiated coverage on Genmab with a new price targetWolfe Research initiated coverage of Genmab with a rating of Outperform and set a new price target of $32.00
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
GMAB FAQ
7 questionsWhat does Genmab A/S do?
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers...Where does GMAB stock trade?
Genmab A/S (GMAB) is listed on NASDAQ.What sector and industry is GMAB in?
Genmab A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Genmab A/S go public?
Genmab A/S (GMAB) completed its IPO in 2019.What are analysts saying about GMAB?
Genmab A/S has had 8 recent analyst actions on file. The most recent action was from Truist: Buy with a $4000.00 price target on 2026-05-27. Recent price targets range from $3200.00 to $4300.00.What companies are similar to GMAB?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GMAB side-by-side with any of them on Quantisnow.How can I track GMAB on Quantisnow?
Quantisnow aggregates Genmab A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GMAB to receive live email and push alerts on every new disclosure.